Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Peeters, M; Callaert, J; Lansink, W; Brodmann, M; Werner, M; Keirse, K; Gouëffic, Y; Verbist, J; Maene, L; Hendriks, JM; Brunet, J; Ducasse, E; Levent, K; Sauguet, A; Vernez, E; Deloose, KR.
Head-to-head comparison of two paclitaxel-coated balloons for femoropopliteal lesions: 3-year results from the BIOPACT RCT.
J Cardiovasc Surg (Torino). 2025; 66(6):557-565
Doi: 10.23736/S0021-9509.25.13399-5
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Brodmann Marianne
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Over the past decade, drug-coated balloons (DCBs) delivering paclitaxel have become widely used for the treatment of peripheral artery disease (PAD). The safety and efficacy of various DCBs have been extensively studied, but differences in device design and drug delivery matrices may influence outcomes. The publication aim was to report long-term safety and efficacy data of the Passeo-18 Lux DCB for the treatment of symptomatic PAD due to stenosis, restenosis or occlusion of the femoral and/or popliteal arteries. METHODS: Three hundred and two patients were randomized 1:1 and assigned to the Passeo-18 Lux DCB (study device) group or to the IN.PACT Admiral DCB (control device) group for testing of noninferiority. An efficacy endpoint was freedom from clinically-driven target lesion revascularization (CD-TLR) at 36 months. In terms of safety, a composite endpoint of freedom from device-/procedure-related death at 30 days post-index procedure, - major target limb amputation and clinically-driven target vessel revascularization (CD-TVR) at 36 months was investigated. RESULTS: At 36 months, freedom from CD-TLR-was achieved in 119 out of 128 patients in the IN.PACT Admiral group (93.0%) and in 116 out of 127 patients in the Passeo-18 Lux group (91.3%). The null hypothesis of inferiority was rejected with a P value of 0.0095, confirming the non-inferiority of Passeo-18 Lux compared to IN.PACT Admiral in terms of efficacy. Both treatment groups demonstrated sustained clinical improvement, as shown by the evolution of the Rutherford Clinical Category (RCC). At 36 months, the mean change in target limb RCC class compared to baseline was -2.5 in both groups, indicating comparable and significant clinical improvement over time. CONCLUSIONS: The Passeo-18 Lux and the IN.PACT Admiral DCBs demonstrate comparable results with excellent effectiveness and safety through 36 months for femoropopliteal interventions.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Paclitaxel - administration & dosage, adverse effects
- Popliteal Artery - physiopathology, diagnostic imaging
- Peripheral Arterial Disease - therapy, physiopathology, diagnostic imaging, mortality
- Femoral Artery - physiopathology, diagnostic imaging
- Aged - administration & dosage
- Male - administration & dosage
- Female - administration & dosage
- Coated Materials, Biocompatible - administration & dosage
- Cardiovascular Agents - administration & dosage, adverse effects
- Angioplasty, Balloon - instrumentation, adverse effects, mortality
- Time Factors - administration & dosage
- Vascular Access Devices - administration & dosage
- Middle Aged - administration & dosage
- Equipment Design - administration & dosage
- Treatment Outcome - administration & dosage
- Limb Salvage - administration & dosage
- Recurrence - administration & dosage
- Vascular Patency - administration & dosage
- Aged, 80 and over - administration & dosage
- Constriction, Pathologic - administration & dosage
- Amputation, Surgical - administration & dosage